[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exagen Inc (XGN)

Exagen Inc (XGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,992
  • Shares Outstanding, K 24,225
  • Annual Sales, $ 66,580 K
  • Annual Income, $ -19,950 K
  • EBIT $ -11 M
  • EBITDA $ -8 M
  • 60-Month Beta 2.05
  • Price/Sales 2.40
  • Price/Cash Flow N/A
  • Price/Book 13.29

Options Overview Details

View History
  • Implied Volatility 134.41% (-1.15%)
  • Historical Volatility 110.49%
  • IV Percentile 17%
  • IV Rank 6.73%
  • IV High 933.06% on 02/18/26
  • IV Low 76.76% on 05/28/26
  • Expected Move (DTE 1) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 421
  • Open Int (30-Day) 332
  • Expected Range 7.50 to 7.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 2
  • High Estimate $-0.17
  • Low Estimate $-0.20
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.09 +83.37%
on 07/28/26
7.62 -1.57%
on 08/20/26
+2.82 (+60.26%)
since 07/20/26
3-Month
3.77 +98.94%
on 05/21/26
7.62 -1.57%
on 08/20/26
+3.67 (+95.82%)
since 05/20/26
52-Week
2.59 +189.58%
on 03/30/26
12.23 -38.68%
on 10/27/25
-2.34 (-23.78%)
since 08/20/25

Most Recent Stories

More News
Exagen Inc. Reports Second Quarter 2026 Financial Results

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance...

XGN : 7.58 (+2.02%)
Exagen Inc. to Participate in Upcoming Investor Conference

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference:...

XGN : 7.58 (+2.02%)
Exagen to Announce Second Quarter Financial Results on August 4, 2026

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026,...

XGN : 7.58 (+2.02%)
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier,...

XGN : 7.58 (+2.02%)
Exagen Q1 Earnings Call Highlights

Exagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption...

XGN : 7.58 (+2.02%)
Exagen Inc. Reports First Quarter 2026 Results

CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026,...

XGN : 7.58 (+2.02%)
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026,...

XGN : 7.58 (+2.02%)
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE ® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026...

XGN : 7.58 (+2.02%)
Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences:...

XGN : 7.58 (+2.02%)
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025,...

XGN : 7.58 (+2.02%)

Business Summary

Exagen Inc. is engaged in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases. It developed and commercialises testing products under AVISE brand. Exagen Inc. is based in Vista, California.

See More

Key Turning Points

3rd Resistance Point 8.44
2nd Resistance Point 7.94
1st Resistance Point 7.69
Last Price 7.58
1st Support Level 6.94
2nd Support Level 6.44
3rd Support Level 6.19

See More

52-Week High 12.23
Fibonacci 61.8% 8.55
Last Price 7.58
Fibonacci 50% 7.41
Fibonacci 38.2% 6.27
52-Week Low 2.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.